Lerisetron: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{{Drugbox | Verifiedfields = changed | verifiedrevid = 462090141 | IUPAC_name = 1-benzyl-2-piperazin-1-yl-1''H''-benzimidazole | image = Lerisetron.png | width = 220 <!--Clin...") |
No edit summary |
||
| Line 49: | Line 49: | ||
| synonyms = Lerisetron | | synonyms = Lerisetron | ||
}} | }} | ||
==Overview== | |||
'''Lerisetron''' ('''F-0930-RS''') is a drug which acts as an [[Antagonist (pharmacology)|antagonist]] at the [[5-HT3 receptor|5HT<sub>3</sub>]] [[Receptor (biochemistry)|receptor]]<ref>Orjales A, Mosquera R, Labeaga L, Rodes R. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation. ''Journal of Medicinal Chemistry''. 1997 Feb 14;40(4):586-93. PMID 9046349</ref> It is a potent [[antiemetic]]<ref>Gomez-de-Segura IA, Grande AG, De Miguel E. Antiemetic effects of Lerisetron in radiation-induced emesis in the dog. ''Acta Oncologica''. 1998;37(7-8):759-63. PMID 10050999</ref><ref>Cooper M, Sologuren A, Valiente R, Smith J. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers. ''Arzneimittelforschung''. 2002;52(9):689-94. PMID 12404884</ref> and is currently in [[clinical trials]] for the treatment of nausea associated with cancer [[chemotherapy]].<ref>Huckle R. Lerisetron. FAES. ''Current Opinion in Investigational Drugs''. 2003 Jul;4(7):874-7. PMID 14619411</ref> | '''Lerisetron''' ('''F-0930-RS''') is a drug which acts as an [[Antagonist (pharmacology)|antagonist]] at the [[5-HT3 receptor|5HT<sub>3</sub>]] [[Receptor (biochemistry)|receptor]]<ref>Orjales A, Mosquera R, Labeaga L, Rodes R. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation. ''Journal of Medicinal Chemistry''. 1997 Feb 14;40(4):586-93. PMID 9046349</ref> It is a potent [[antiemetic]]<ref>Gomez-de-Segura IA, Grande AG, De Miguel E. Antiemetic effects of Lerisetron in radiation-induced emesis in the dog. ''Acta Oncologica''. 1998;37(7-8):759-63. PMID 10050999</ref><ref>Cooper M, Sologuren A, Valiente R, Smith J. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers. ''Arzneimittelforschung''. 2002;52(9):689-94. PMID 12404884</ref> and is currently in [[clinical trials]] for the treatment of nausea associated with cancer [[chemotherapy]].<ref>Huckle R. Lerisetron. FAES. ''Current Opinion in Investigational Drugs''. 2003 Jul;4(7):874-7. PMID 14619411</ref> | ||
| Line 54: | Line 56: | ||
== References == | == References == | ||
{{reflist}} | {{reflist|2}} | ||
[[Category:5-HT3 antagonists]] | [[Category:5-HT3 antagonists]] | ||
[[Category:Piperazines]] | [[Category:Piperazines]] | ||
[[Category:Benzimidazoles]] | [[Category:Benzimidazoles]] | ||
Latest revision as of 21:03, 29 June 2012
 | |
| Clinical data | |
|---|---|
| Synonyms | Lerisetron |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C18H20N4 |
| Molar mass | 292.378 g/mol |
| |
  (what is this?) (verify) | |
Overview
Lerisetron (F-0930-RS) is a drug which acts as an antagonist at the 5HT3 receptor[1] It is a potent antiemetic[2][3] and is currently in clinical trials for the treatment of nausea associated with cancer chemotherapy.[4]
References
- ↑ Orjales A, Mosquera R, Labeaga L, Rodes R. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation. Journal of Medicinal Chemistry. 1997 Feb 14;40(4):586-93. PMID 9046349
- ↑ Gomez-de-Segura IA, Grande AG, De Miguel E. Antiemetic effects of Lerisetron in radiation-induced emesis in the dog. Acta Oncologica. 1998;37(7-8):759-63. PMID 10050999
- ↑ Cooper M, Sologuren A, Valiente R, Smith J. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers. Arzneimittelforschung. 2002;52(9):689-94. PMID 12404884
- ↑ Huckle R. Lerisetron. FAES. Current Opinion in Investigational Drugs. 2003 Jul;4(7):874-7. PMID 14619411
Categories:
- Pages with script errors
- Drugs not assigned an ATC code
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- 5-HT3 antagonists
- Piperazines
- Benzimidazoles